Published in Oncotarget on May 03, 2017
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Hepatocellular carcinoma. Lancet (2012) 18.09
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther (2009) 4.98
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology (2010) 1.80
Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology (2015) 1.60
Biology of the TAM receptors. Cold Spring Harb Perspect Biol (2013) 1.59
The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem (1995) 1.52
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol (2015) 1.46
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer (1992) 1.45
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.37
Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci (2007) 1.24
Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost (2010) 1.22
Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol (2011) 1.17
Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) (2011) 1.05
Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells. Hepatology (2006) 1.02
Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology (2007) 0.96
Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.95
Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem (2009) 0.95
Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis (2012) 0.91
Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus. Lupus (2014) 0.89
Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer (2014) 0.89
Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer (2015) 0.86
New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer (2008) 0.85
Growth arrest-specific protein 6 deficiency impairs liver tissue repair after acute toxic hepatitis in mice. J Hepatol (2009) 0.85
The significance of serum AFP cut-off values, 20 and 400 ng/mL in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference. Hepatogastroenterology (2012) 0.83
Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep (2016) 0.83
Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget (2015) 0.83
Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One (2016) 0.80
Plasma concentrations of sAxl are associated with severe preeclampsia. Clin Biochem (2013) 0.79
Inducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver disease. Histol Histopathol (2015) 0.78
Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay. Assay Drug Dev Technol (2016) 0.77
Hepcidin knockout mice fed with iron-rich diet develop chronic liver injury and liver fibrosis due to lysosomal iron overload. J Hepatol (2014) 2.15
Trends in quality of screening colonoscopy in Austria. Endoscopy (2016) 2.04
Serum WFA(+) -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int (2015) 2.02
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol (2015) 1.65
High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. Endoscopy (2014) 1.47
Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol (2006) 1.10
The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response. Hepatology (2015) 1.07
Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol (2005) 1.03
Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One (2014) 1.02
Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int (2005) 1.01
Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One (2014) 0.97
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol (2015) 0.96
Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta (2014) 0.95
Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol (2016) 0.94
Non-invasive fibrosis score for hepatitis delta. Liver Int (2016) 0.90
Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.86
Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol (2014) 0.86
Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma. J Gastroenterol Hepatol (2007) 0.85
Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease. PLoS One (2016) 0.84
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int (2016) 0.84
Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res (2007) 0.83
Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget (2016) 0.82
A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery (2015) 0.82
Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis (2012) 0.81
Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology (2016) 0.80
A greater proportion of liver transplant candidates have colorectal neoplasia than in the healthy screening population. Clin Gastroenterol Hepatol (2014) 0.80
Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology (2016) 0.80
Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol (2014) 0.80
Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis. PLoS One (2015) 0.80
Simultaneous multicentric occurrence of early hepatocellular carcinoma in a patient with persistent alpha-fetoprotein elevation. Hepatol Res (2007) 0.78
Combined effects of the TM6SF2 rs58542926, PNPLA3 rs738409 and MBOAT7 rs641738 variants on NAFLD severity: multicentre biopsy-based study. J Lipid Res (2016) 0.77
Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients. Eur J Cancer (2015) 0.77
Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One (2015) 0.77
Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations. J Hepatol (2015) 0.77
Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. J Trace Elem Med Biol (2016) 0.76
The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget (2017) 0.76
Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan. Hepatol Res (2015) 0.76
Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Med (2014) 0.76
Transnasal Endoscope Locked in a Bent Position Causing Difficult Withdrawal. ACG Case Rep J (2014) 0.75
Long- and short-term outcomes of ERCP for bile duct stones in patients over 80 years old compared to younger patients: a propensity score analysis. Endosc Int Open (2015) 0.75
Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases. Biomarkers (2012) 0.75
Dietary sugar intake increases liver tumor incidence in female mice. Sci Rep (2016) 0.75
Response to 'WFA(+) -M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases'. Liver Int (2016) 0.75
Loss of adipose triglyceride lipase is associated with human cancer and induces mouse pulmonary neoplasia. Oncotarget (2016) 0.75
Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PLoS One (2017) 0.75
Reply: To PMID 24913549. Hepatology (2015) 0.75
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study. Wien Klin Wochenschr (2017) 0.75
Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress. Toxicol Sci (2017) 0.75
Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B. J Hepatol (2016) 0.75
The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death Dis (2017) 0.75
Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. Ther Apher Dial (2017) 0.75
Trends in quality of screening colonoscopy in Austria. Endoscopy (2016) 0.75
Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data. J Gastroenterol Hepatol (2017) 0.75
ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function. Liver Cancer (2017) 0.75
SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One (2017) 0.75
Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy. Intervirology (2014) 0.75
Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology (2017) 0.75
Hepatitis B Core-Related Antigen: A Possible Indicator for the Termination of Prophylactic Nucleos(t)ide Analogue Therapy in Patients After Immunosuppressive Therapy. Am J Gastroenterol (2017) 0.75
Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. Antivir Ther (2016) 0.75
Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis. Liver Int (2016) 0.75
Niacin-Associated Acute Hepatotoxicity Leading to Emergency Liver Transplantation. Am J Gastroenterol (2017) 0.75
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay. Liver Int (2016) 0.75
Real world data of daclatasvir and asunaprevir combination therapy for HCV genotype 1b infection in patients with renal dysfunction. Clin Gastroenterol Hepatol (2016) 0.75
Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series. Obes Surg (2017) 0.75